Morgan Stanley’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-162,905
| Closed | -$16.6M | – | 7747 |
|
|
2023
Q2 | $16.6M | Sell |
162,905
-80,156
| -33% | -$7.59M | ﹤0.01% | 2658 |
|
|
2023
Q1 | $22.1M | Sell |
243,061
-490,671
| -67% | -$28.8M | ﹤0.01% | 2316 |
|
|
2022
Q4 | $27.9M | Buy |
733,732
+420,490
| +134% | +$14.5M | ﹤0.01% | 2014 |
|
|
2022
Q3 | $7.87M | Buy |
313,242
+47,030
| +18% | +$1.3M | ﹤0.01% | 3212 |
|
|
2022
Q2 | $8.09M | Sell |
266,212
-40,189
| -13% | -$1.2M | ﹤0.01% | 3291 |
|
|
2022
Q1 | $10M | Buy |
306,401
+43,804
| +17% | +$1.3M | ﹤0.01% | 2906 |
|
|
2021
Q4 | $6.92M | Buy |
262,597
+98,122
| +60% | +$7.59M | ﹤0.01% | 3372 |
|
|
2021
Q3 | $16.5M | Buy |
164,475
+95,895
| +140% | +$11.2M | ﹤0.01% | 2291 |
|
|
2021
Q2 | $9.71M | Buy |
68,580
+6,193
| +10% | +$699K | ﹤0.01% | 3029 |
|
|
2021
Q1 | $6.22M | Buy |
62,387
+25,539
| +69% | +$2.98M | ﹤0.01% | 3184 |
|
|
2020
Q4 | $4.55M | Buy |
36,848
+2,021
| +6% | +$266K | ﹤0.01% | 3362 |
|
|
2020
Q3 | $3.39M | Sell |
34,827
-55,466
| -61% | -$6.93M | ﹤0.01% | 3113 |
|
|
2020
Q2 | $14.1M | Sell |
90,293
-24,571
| -21% | -$3.74M | ﹤0.01% | 1678 |
|
|
2020
Q1 | $16.6M | Buy |
114,864
+59,563
| +108% | +$11.5M | ﹤0.01% | 1415 |
|
|
2019
Q4 | $11.3M | Buy |
55,301
+27,524
| +99% | +$5.02M | ﹤0.01% | 2295 |
|
|
2019
Q3 | $2.23M | Buy |
27,777
+6,218
| +29% | +$528K | ﹤0.01% | 3678 |
|
|
2019
Q2 | $2.03M | Sell |
21,559
-11,148
| -34% | -$963K | ﹤0.01% | 3752 |
|
|
2019
Q1 | $2.8M | Sell |
32,707
-19,171
| -37% | -$1.59M | ﹤0.01% | 3292 |
|
|
2018
Q4 | $2.91M | Sell |
51,878
-3,763
| -7% | -$230K | ﹤0.01% | 3460 |
|
|
2018
Q3 | $4.55M | Buy |
55,641
+2,291
| +4% | +$161K | ﹤0.01% | 3285 |
|
|
2018
Q2 | $1.86M | Buy |
53,350
+5,504
| +12% | +$168K | ﹤0.01% | 4140 |
|
|
2018
Q1 | $982K | Buy |
47,846
+12,835
| +37% | +$330K | ﹤0.01% | 4554 |
|
|
2017
Q4 | $992K | Buy |
35,011
+7,099
| +25% | +$198K | ﹤0.01% | 4545 |
|
|
2017
Q3 | $868K | Buy |
27,912
+8,848
| +46% | +$266K | ﹤0.01% | 4527 |
|
|
2017
Q2 | $603K | Buy |
19,064
+1,862
| +11% | +$45.8K | ﹤0.01% | 4683 |
|
|
2017
Q1 | $390K | Sell |
17,202
-8,856
| -34% | -$219K | ﹤0.01% | 4979 |
|
|
2016
Q4 | $568K | Buy |
26,058
+10,448
| +67% | +$264K | ﹤0.01% | 4860 |
|
|
2016
Q3 | $411K | Buy |
15,610
+8,567
| +122% | +$170K | ﹤0.01% | 4634 |
|
|
2016
Q2 | $139K | Buy |
+7,043
| New | +$137K | ﹤0.01% | 5099 |
|
Other funds holding RETA
Morgan Stanley's RETA Position: Q3 2023 in Review
Morgan Stanley sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 162,905 shares — an estimated $16.6M sold.
Morgan Stanley first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $27.9M in Q4 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Morgan Stanley reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Morgan Stanley sold 162,905 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $16.6M.
- Morgan Stanley first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Morgan Stanley's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $27.9M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.